Among patients with type 2 diabetes with chronic kidney disease with GFR > 25 mL/min/1.73 and urinary albumin of 300 mg/g creatinine, 137 (73.9%) physicians prescribe patients empagliflozin, which is a good practice among patients with diabetic kidney disease to prevent and delay the progression of the disease. This evidence concerns the gene ALB and type 2 diabetes mellitus.